Safety Reading Notes

Read safety context beside the research guide.

The TRPA1 cannabinoid target source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 30697147

PubMed For Dummies Article

TRPA1 cannabinoid target Evidence Review: the long-form source walk-through

Quick read
  • TRPA1 cannabinoid target currently has 18 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 30697147
  • The evidence classes most visible in the row language are insufficient (10), and mechanistic or pharmacological (8). PMID 35483477
  • The study-design language most visible in the row language is Narrative or expert review (7), Animal study (5), Cellular or in vitro study (2), and other mapped categories (1). PMID 34259916
  • The repeated topics are TRPA1 (18), which tells the reader where to start opening PubMed and DOI links. PMID 29240420

Start with the research question

TRPA1 cannabinoid target is built from 18 source-backed evidence row(s) and 18 research source(s). The current evidence classes read as insufficient (10), and mechanistic or pharmacological (8), and the study-design language most often reads as Narrative or expert review (7), Animal study (5), Cellular or in vitro study (2), and other mapped categories (1). PMID 30697147

The row-level question is not simply whether TRPA1 cannabinoid target is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are TRPA1 (18). PMID 32051870

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 19070372

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 32051870

Mechanistic evidence 8 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 24756722

Limits and uncertainty 10 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 39368566

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 38219731

Where this page has the most source density

The largest bucket surfaced for this page is TRPA1: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is TRPA1: mechanistic or pharmacological, which gives readers another way to see what the literature repeatedly circles. PMID 30697147

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 32051870

Bucket chapters: what the literature is circling

TRPA1: insufficient

10 research sources 10 rows (1030-1045) Evidence class: insufficient

This bucket summarizes source-backed rows focused on TRPA1: insufficient. It currently draws from 10 research source(s), so the exact study type matters. PMID 30697147

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 30697147

  • Evidence row 1030

    THC modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30697147

  • Evidence row 1045

    CBD modulates TRPA1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or... PMID 35605018

TRPA1: mechanistic or pharmacological

8 research sources 8 rows (1035-1047) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on TRPA1: mechanistic or pharmacological. It currently draws from 8 research source(s), so the exact study type matters. PMID 32051870

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 32051870

  • Evidence row 1035

    Cannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling... PMID 32051870

  • Evidence row 1047

    CBD modulates TRPA1; evidence class: mechanistic or pharmacological (outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 38408345

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (8 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 30697147

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 32051870

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 28120232
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 21727026
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 25065940

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 30697147

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 32051870

Source-reading checklist for TRPA1 cannabinoid target

  1. Open the linked PubMed or DOI record. PMID 21645531
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 32965166
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 31446830
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 35605018
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 32873774

Source Notes

TRPA1 cannabinoid target source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 1030

    THC modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30697147

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
  2. Evidence row 1031

    CBD modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 35483477

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological effects of cannabidiol by transient receptor potential channels.
  3. Evidence row 1032

    THC modulates TRPA1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 34259916

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
  4. Evidence row 1033

    THC modulates TRPA1; evidence class: insufficient (outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 29240420

    Evidence class: insufficient. Source: Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids.
  5. Evidence row 1034

    Cannabinoids modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 19070372

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.
  6. Evidence row 1035

    Cannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 32051870

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modification of TRPV4 activity by acetaminophen.
  7. Evidence row 1036

    Cannabinoids modulates TRPA1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 24756722

    Evidence class: insufficient; Study design: Narrative or expert review. Source: TRPA1.
  8. Evidence row 1037

    THC modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 39368566

    Evidence class: mechanistic or pharmacological. Source: Identification of the TRPA1 cannabinoid-binding site.
  9. Evidence row 1038

    Cannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 38219731

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Affinin, Isolated from Heliopsis longipes, Induces an Antihypertensive Effect That Involves CB1 Cannabinoid Receptors and TRPA1 and TRPV1 Channel Activation.
  10. Evidence row 1039

    THC modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 28120232

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Targets of the Phytocannabinoids: A Complex Picture.
  11. Evidence row 1040

    Cannabinoids modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 21727026

    Evidence class: insufficient; Study design: Narrative or expert review. Source: G-protein coupled receptors regulating cough.
  12. Evidence row 1041

    Endocannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 25065940

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
  13. Evidence row 1042

    Cannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 21645531

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons.
  14. Evidence row 1043

    CBD modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 32965166

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol activation of vagal afferent neurons requires TRPA1.
  15. Evidence row 1044

    CBD modulates TRPA1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 31446830

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Myrcene and terpene regulation of TRPV1.
  16. Evidence row 1045

    CBD modulates TRPA1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 35605018

    Evidence class: insufficient; Study design: Systematic review. Source: Systematic Review on Transdermal/Topical Cannabidiol Trials: A Reconsidered Way Forward.
  17. Evidence row 1046

    CBD modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 32873774

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts.
  18. Evidence row 1047

    CBD modulates TRPA1; evidence class: mechanistic or pharmacological (outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 38408345

    Evidence class: mechanistic or pharmacological. Source: Phytochemical Characterization and TRPA1/TRPM8 Modulation Profile of the Cannabigerol-Rich Cannabis sativa L. Chemotype IV.